Istmed Spółka z Ograniczoną Odpowiedzialnością (KRS 0000674312, NIP 5492447205) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. Istmed operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since April 25, 2017. Istmed's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Istmed
Identity
- Name
- Istmed Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 25, 2017
- Registry status as of
- December 3, 2025
- Latest entry
- July 14, 2025
- Founding act
- 02.03.2017 REP A NR 639/2017 NOTARIUSZ JUSTYNA TUSZYŃSKA KANCELARIA NOTARIALNA W KRAKOWIE
Articles of association history (2)
- March 2, 2017: 02.03.2017 REP A NR 639/2017 NOTARIUSZ JUSTYNA TUSZYŃSKA KANCELARIA NOTARIALNA W KRAKOWIE
- September 17, 2020: 17.09.2020 R., KANCELARIA NOTARIALNA W KRAKOWIE, NOTARIUSZ WOJCIECH ZARZYCKI, REP. A NR 19448/2020, ZMIANA §1 UST. 3
Activities
Address and contact
- Address
- UL. WOLSKA, 1, 30-663, KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- KRAKÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Istmed
Credibility rating
45.4 / 100
Average credibility
Insolvency risk
Very low
Elevated threat
Closure risk
34
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/9 yrs
Board changes
0
0/9 yrs
PKD changes
1
1/9 yrs
Name changes
0
0/9 yrs
Data from 9 years of registry activity.
Credibility history
Payment reliability score from 2019–2024
Current: D (45/100)
Trend: stable (-0.4 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2019–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Istmed
Founded
April 25, 2017
9 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
5.0 K PLN
98 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
6 years
2019–2024 · profitable: 3/6
Registry entries
27
latest: July 14, 2025
Risk signals
Revenue
0 PLN
2024
Net profit
-2.6 K PLN
2024
Assets
17.8 K PLN
2024
Equity
13.9 K PLN
2024
Valuation
11.7 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Istmed.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1m capex (+212%), a PLN 1.10 dividend three years running, Cydr Lubelski and Romanian Zarea as the premium engines
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8m of revenue and PLN 49.0m of net profit, while raising capex by 212% to PLN 48.1m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9m acquisition of a Romanian company. Despite the heavy investment cycle the board is keeping the PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7bn (+13% YoY), EBITDA of PLN 56m (+63%) and net profit of PLN 9.3m - a return to the black after a PLN 10m loss in 2024. Poland grew 31%, but CEE was under FX pressure (hryvnia -11% versus the zloty), and a weak Q4 (EBITDA -71% YoY) prompted the supervisory board to cut the 2026 EBITDA target from PLN 100m to PLN 90m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
